CHM.CN Stock Surges 900% in April 2026 Trading Session

Waverunner Capital Inc. (CHM.CN) delivered a stunning 900% surge on April 22, 2026, climbing to C$0.05 per share on the Canadian CNQ exchange. This dramatic spike marks one of the most extreme single-day moves we’ve tracked. The venture capital firm, based in North Vancouver, recently rebranded from Chemistree Technology Inc. in June 2024. CHM.CN stock now trades at its 50-day average of C$0.0424, signaling potential consolidation ahead. With a market cap of C$37.2 million and 744 million shares outstanding, this penny stock remains highly volatile. Investors should approach with caution given the extreme price swings and negative earnings metrics.

CHM.CN Stock Price Action and Volume Surge

CHM.CN stock exploded from C$0.005 to C$0.05 in a single trading session, representing a 900% gain. The stock hit both its day low and day high at C$0.05, showing concentrated buying pressure. Year-to-date performance reveals a 400% five-day gain and 400% one-year return, though the stock remains down 80.4% over five years. Average daily volume sits at 28,908 shares, relatively modest for such price volatility. The previous close of C$0.005 suggests this move came from extremely thin liquidity. Track CHM.CN on Meyka for real-time updates on this high-volatility mover.

Waverunner Capital Inc. Business Model and Focus

Waverunner Capital Inc. operates as a venture capital firm specializing in early-stage investments, seed funding, and bridge financing across Europe and North America. The company targets equity investments between C$500,000 and C$1 million, with enterprise values between C$2 million and C$5 million. CEO Karl Eric Kottmeier leads the firm from its North Vancouver headquarters at 828 Harbourside Drive. Waverunner invests through its own balance sheet and personal capital, focusing on resources, renewable energy (wind and solar), plant-based wellness, and consumer-targeted biotechnology. This diversified portfolio approach reflects the firm’s broad investment thesis across multiple growth sectors.

Financial Metrics and Profitability Concerns

CHM.CN stock shows significant financial headwinds. The company reports a negative EPS of -C$0.01 and a negative PE ratio of -5.0, indicating ongoing losses. Net income per share stands at -C$0.0595, while operating cash flow per share is -C$0.0045. The current ratio of 0.097 raises liquidity concerns, suggesting the firm may struggle to meet short-term obligations. Book value per share is deeply negative at -C$0.1422. These metrics reflect a company in financial distress, burning cash rather than generating profits. Investors must understand that Waverunner remains unprofitable and faces structural challenges.

Market Sentiment and Trading Activity

The 900% spike in CHM.CN stock reflects extreme market sentiment swings typical of penny stocks. Trading activity remains concentrated, with average volume of just 28,908 shares daily. Such thin liquidity amplifies price movements on modest buy or sell orders. The stock’s year high of C$0.10 and year low of C$0.05 show a compressed trading range despite the dramatic intraday surge. This pattern suggests retail investor interest rather than institutional accumulation. Market participants should recognize that penny stocks like CHM.CN can experience violent reversals just as quickly as rallies, making risk management essential.

Meyka AI Grade and Investment Assessment

Meyka AI rates CHM.CN with a grade of B based on a score of 61.34. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The rating suggests a HOLD recommendation, indicating the stock offers neither compelling upside nor immediate downside risk at current levels. However, this grade is not guaranteed and should not be treated as financial advice. The negative profitability metrics and weak balance sheet temper any optimism. Investors should conduct thorough due diligence before committing capital to this venture capital firm.

Healthcare Sector Context and Competitive Position

Waverunner Capital operates within the Healthcare sector, classified under Drug Manufacturers – Specialty & Generic. The broader Healthcare sector in Canada shows mixed performance, with an average PE ratio of 16.38 and negative average ROA of -8.21%. Top Healthcare performers like UnitedHealth Group (UNH.NE) and Thermo Fisher Scientific (TMO.NE) dwarf Waverunner’s C$37.2 million market cap. CHM.CN’s venture capital model differs from traditional pharma manufacturers, positioning it as a minority player. The sector’s defensive characteristics contrast sharply with Waverunner’s high-risk, high-volatility profile, making direct comparisons difficult.

Final Thoughts

CHM.CN stock’s 900% surge on April 22, 2026, captures the extreme volatility inherent in penny stocks and venture capital firms. While the dramatic price action grabs headlines, the underlying fundamentals tell a cautionary tale. Waverunner Capital Inc. remains unprofitable with negative cash flow, weak liquidity, and a deeply negative book value. The Meyka AI HOLD rating reflects balanced risk-reward, but investors must recognize the speculative nature of this investment. The company’s venture capital model offers potential upside if portfolio companies succeed, yet current financial metrics provide no margin for error. Before investing in CHM.CN stock, conduct thorough research, understand your risk tolerance, and consider this a high-risk, high-reward opportunity suitable only for experienced traders. Past performance is not indicative of future results.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.